A number of chemotherapeutic agents, such as platinum drugs, nitrogen mustards, and chloroethylnitrosoureas, act by forming bifunctional DNA adducts. It is likely that abortive attempts to replicate and/or repair the damaged DNA cause chromosome aberrations and breakage, leading to cell death. Any substantial increase in cellular capacity to repair damaged DNA may result in resistance to chemotherapeutic agents. In this review, we examine the types of DNA adducts formed by the major classes of chemotherapeutic agents, the enzymatic pathways that play a role in the repair of those adducts, the evidence that DNA repair is enhanced in drugresistant cell lines and tumors, and strategies for utilizing selective inhibition of DNA repair to overcome
A number of widely used chemotherapeutic drugs act by forming bifunctional DNA adducts. The exact mechanism by which these adducts cause cell death is not known. However, it is most likely that abortive attempts to replicate and/or repair the damaged DNA cause the formation of double-strand breaks or single-strand gaps in the DNA, which lead to chromosome aberrations and breakage during mitosis. Ultimately, either the DNA adducts themselves or the damage to the DNA caused by these adducts triggers apoptosis and/or other mechanisms of cell death. Thus, it has been considered likely that any substantial increase in the repair of bifunctional adducts would cause resistance to these chemotherapeutic agents. Considerable effort over the past 25 years has been devoted to determining the contribution of DNA repair pathways to drug resistance and to developing strategies for interfering with repair as a means of overcoming resistance. In this review, we will examine the types of adducts formed by the major classes of chemotherapeutic agents, the enzymatic pathways responsible for repair of each of those adducts, the evidence for enhancement of DNA repair in drug-resistant cell lines and tumors, and future strategies for utilizing selective inhibition of repair pathways to overcome drug resistance and improve therapeutic index. We have not attempted to include in this review those chemotherapeutic agents that form monofunctional adducts, those that intercalate into DNA, those that cause single-or double-strand breaks as their primary mechanism of action, or those purine and pyrimidine analogues that are incorporated into DNA.
cer, ovarian cancer, and breast cancer. Cyclophosphamide requires metabolism for activity (16, 17) ; however, for the purposes of this review, we will not distinguish between cyclophosphamide and its active metabolites. The analysis of the adducts formed by the nitrogen mustards is complicated by the metabolism of cyclophosphamide, the tendency of the N G intrastrand diadducts, and an approximately equal percentage of N 3 C-N'G interstrand diadducts (25) . The N 3 C-N'G interstrand diadducts are particularly interesting because they are formed by the initial reaction of the CENUs with the O 6 atom of guanine followed by a relatively rapid intermolecular rearrangement to form an intramolecular N 1 , O 6 -ethanoguanine adduct. This is followed by the subsequent cleavage of the exocyclic C-0 bond and reaction with the N 3 atom of cytosine in the complementary strand to give the N 3 C-N ! G diadduct (26, 27) . In studies of different CENUs (28, 29) , the cytotoxicity appears to be proportional to interstrand cross-link formation (compared with monoadduct formation). The relative cytotoxicity of the intrastrand diadduct is not clear, but studies of repair mechanisms (see below) suggest that both contribute to the cytotoxicity of CENUs. For more detailed information on the adducts formed by CENUs, the reader is directed to reviews by Ludlum (30) and Wiencke and Wiemels (31) .
Other Alkylating Agents
The alkyl sulfonate busulfan has been used for the treatment of chronic myelogenous leukemia. The reaction of busulfan with DNA has been less well characterized than for the other alkylating agents because of its low reactivity and the relatively rapid depurination of the adducts formed (32) (33) (34) . Busulfan has been shown to react with the N 7 atom of guanine (32, 33) , but it has less selectivity for guanine than the nitrogen mustards (33) . Tong and Ludlum (32) have demonstrated the formation of N 7 G-N 7 G diadducts in busulfan-treated DNA, but it is not clear whether those adducts are primarily intrastrand or interstrand (52, 55) . However, the ability to form interstrand cross-links is proportional to the cytotoxicity of the alkyl sulfonates as a group (34) .
Mitomycin C (MMC) has been used in combination with other chemotherapeutic agents for the treatment of a wide variety of solid tumors, especially anal squamous cell carcinoma and superficial bladder carcinoma (35, 36) . MMC is metabolized prior to its interactions with DNA. However, the effects of MMC metabolism on adduct formation will not be considered in this review. MMC metabolites react preferentially with the Nã tom of guanine (55,5<5) . When MMC metabolites react with DNA in vitro, there is a 3.6:1 ratio of interstrand to intrastrand diadducts formed (37) . However, in cell culture, MMC appears to form roughly equivalent numbers of intrastrand and interstrand diadducts (35) . As for the other alkylating agents, there is an association between cytotoxicity and interstrand cross-link formation (38, 39) . The cytotoxicity of the other MMC adducts has not been determined. For a more detailed description of the chemistry and biology of MMC and related compounds, the reader is directed to the review by Verweij and Pinedo (36) .
Repair of Genotoxic Lesions
DNA repair encompasses the molecular reactions that eliminate damaged or mismatched nucleotides from DNA. The repair mechanisms are classified into four general categories depending on the basic chemical reactions involved in making the correction: 1) direct repair, 2) base-excision repair, 3) nucleotide-excision repair, and 4) mismatch repair. The mechanisms of these repair processes have been described in detail in previous reviews (40) (41) (42) . In direct repair, the chemical bond linking the base to a substituent is broken. In base-excision repair, the damaged nucleotide is removed in two steps. First, the modified base is released by a glycosylase, which cleaves the glycosylic bond linking the deoxyribose to the base, and then the abasic (AP [i.e., apurinic or apyrimidinic]) sugar is released by a pair of AP endonucleases. In mismatch and nucleotide-excision repair, an adenosine triphosphate-dependent multisubunit nuclease removes the mismatch or the damage in the form of a mononucleotide (mismatch repair) or a 27-to 29-nucleotidelong oligonucleotide (nucleotide-excision repair). In mismatch repair, the misincorporated nucleotide is removed and replaced with the correct one. In addition to these repair systems, cells possess several ill-defined molecular mechanisms enabling them to generate two uninterrupted duplexes from a damaged chromosome without removing the damage; these mechanisms are referred to as postreplication repair mechanisms, even though no repair has taken place in the strict sense of the word (43, 44) . Nevertheless, the generation of two uninterrupted chromosomes before mitosis does help cells survive the genotoxic stress; hence, the phenomenon is justifiably called DNA repair. The human DNA repair mechanisms are summarized in Fig. 1 and are discussed in more detail below. This enzyme is a 22-kd polypeptide with no cofactor. It repairs DNA via a suicide mechanism by transferring the alkyl group from DNA bases to a specific cysteine residue (found in the amino acid sequence PCHRV) in the enzyme (45) . The best substrate with regard to catalytic efficiency is O 6 -methylguanine. However, the enzyme removes other alkyl groups from the O 6 atom of guanine as well as from the O 4 atom of thymine with varying efficiencies. There is no known human syndrome or disease caused by a mutation in the MGMT gene. However, mouse MGMT-knockout mutants exhibit increased rates of mutations and cancers induced by ethylnitrosourea and perhaps other alkylating agents.
Base-Excision Repair Initiated by Methylpurine-DNA Glycosylase (MPG)
There are three well-characterized DNA glycosylases that initiate base-excision repair of DNA damage (41, 42) . However, we will disuss only MPG here because of its role in repairing damage caused by alkylating chemotherapeutic drugs. The enzyme is most active on 3-methyladenine; thus, it is often referred to as 3-methyladenine-DNA glycosylase. However, the enzyme is active on virtually all alkylated purines, and hence it is also referred to as alkylpurine-DNA glycosylase. The human enzyme is a 33-kd polypeptide with no cofactor. It is a simple glycosylase with no AP-lyase activity. There are no known In Direct Repair, the methyl (or other alkyl groups) at the O 6 position of guanine is transferred to an active-site cysteine residue (represented by -SH) in the enzyme methylguanine-DNA methyltransferase (MGMT). In BaseExcision Repair, the damaged base is removed from the DNA by a DNA glycosylase. Then, an AP (apurinic/ apyrimidinic) lyase incises 3' to the abasic site, and AP endonuclease hydrolyzes 5' to the abasic site to release the deoxyribose (dR) moiety. The resulting one-nucleotide gap is filled by DNA polymerase P and, to a lesser degree, by polymerases 8 and e. The repair patch is one to four nucleotides in length. In NucleotideExcision Repair, an adenosine triphosphate-dependent enzymatic activity resulting from the coordinated actions of six factors including the tnmeric replication repair factor, RPA, and the pentameric transcription/repair factor, TFIIH, incises the 6th phosphodiester bond 3' and the 22nd phosphodiester bond 5' to the lesion (monoadduct or diadduct) and thus excises the damage in a 29-nucleotide-Iong oligomer. The resulting gap is filled by DNA polymerase 8 or e and closed by DNA ligase. In Mismatch Repair, the mismatch is recognized by the MutSa heterodimer and, in the presence of a nick (which could be up to 1000 nucleotides away from the mismatch) and the MutLa heterodimer, the DNA between the nick and the mismatch is removed by either a 3' to 5' or a 5' to 3' exonuclease to a point beyond the mismatch. The resulting single-strand gap is filled by DNA polymerases 8 or e and closed by DNA ligase. XPA, XPC, XPG, XPF-ERCC1 = products of genes corresponding to xeroderma pigmentosum (XP) or excision repair cross-complementing (ERCC) groups A, C. G. F. and 1, respectively: G = guanine; T = thymine; MeG = methylguanine; Pol = DNA polymerase; nt = nucleotide(s): dNMP's = deoxynucleoside monophosphates. For identities of protein components of multimeric repair factors, see text.
human syndromes or animal models associated with MPG deficiency.
Nucleotide-Excision Repair
This is an elaborate repair system that removes bulky lesions from DNA in the form of 27-to 29-nucleotide-long oligomers by incising the damaged strand on both sides of the lesion (46, 47) . The enzyme system, which is also known as the excision nuclease or excinuclease, removes all tested bulky lesions from DNA and also plays a back-up role for other repair systems, since it is capable of removing nonbulky lesions, such as AP sites and O 6 -methylguanine residues. Humans defective in this repair system suffer from xeroderma pigmentosum (XP), a disease characterized by a high incidence of skin cancers caused by the pyrimidine dimers induced by sunlight (48) . By somatic cell genetic analysis, seven human genes, XPA through XPG, have been identified as genes essential for excision repair. In addition, studies with UV radiation-sensitive mutant rodent cell lines and biochemical reconstitution experiments have revealed several additional polypeptides as essential components of the excision nuclease. In total, 14 polypeptides in six complexes are required for the dual incision (49): 1) XPA (p31); 2) RPA (trimeric replication repair factor, containing p70, p34, and pll); 3) TFIIH (transcription factor IIH, containing XPB [p89; also known as ERCC2 {excision repair cross-complementing group 2}], XPD [p80; also known as ERCC3], p62, p44, and p34); 4) XPC (pi25 and p58); 5) XPF (pi 12; also known as ERCC4)-ERCC1 (p33); and 6) XPG (pi35). Recent biochemical studies (46, 47) have provided a detailed understanding of the excision mechanism. Following excision, the gap is filled by the DNA replication proteins RPA, RFC (replication factor C, containing five subunits), PCNA (proliferating cell nuclear antigen), and DNA polymerase 8 or e, and the repair patch is ligated (50) . Because of its complexity and its wide substrate range, excision repair is considered an important potential target for cancer chemotherapy.
Another interesting feature of excision repair is its preference for transcribed regions of the genome (57, 52) This phenomenon is variously referred to as preferential repair, gene-specific repair, or transcription-coupled repair. The basic phenomenon is that the template strand of an actively transcribed gene is repaired twofold to 10-fold more rapidly than the nontranscribed strand (strand-specific repair) and other nontranscribed sequences in general. It appears that the XPC component of the excision nuclease is not required for transcription-coupled repair (55) . The other five components and at least two additional proteins called CSA and CSB are necessary for preferential repair. Humans with mutations in either CSA or CSB genes exhibit Cockayne's syndrome (CS), which manifests neuroskeletal abnormalities but no predisposition to sunlight-induced skin cancer. The molecular mechanism of transcription-coupled repair is not known; however, it appears that only genes transcribed by RNA polymerase II and only lesions that block the progression of this enzyme are subject to transcriptioncoupled repair. It has been suggested that preferential repair is a better indicator of cellular response to genotoxic agents than overall genome repair and that it might be more relevant to measure preferential repair in cases where increased repair is thought to play a role in resistance to chemotherapeutic drugs. However, there is currently no convincing evidence for preferential gene-specific repair in drug-resistant tumor cell lines (see below).
Repair of Interstrand Cross-links
Interstrand cross-links constitute a significant fraction of the DNA lesions introduced by BCNU, nitrogen mustards, and cisplatin. It is known that interstrand cross-links are eliminated from human DNA; however, there are no biochemical data on how this repair is accomplished (42) . Based on the genetic and biochemical evidence from bacterial systems, it is thought that these cross-links are eliminated from DNA by the combined-actions of excision repair and recombination systems. Thus, all excision-repair-defective mutants are expected to be sensitive to cross-linking agents. Indeed, all XP mutants as well as rodent cell lines sensitive to UV irradiation are sensitive to cross-linking agents. Of course, since all interstrand cross-linking agents produce intrastrand cross-links and monoadducts as well, it is difficult to ascribe the sensitivity of these mutants to a lack of cross-link repair. However, the rodent ERCC4 (XPF) and ERCC1 mutants are exquisitely sensitive to cross-linking agents such as MMC (54), suggesting that the XPF-ERCC1 complex plays a unique role in cross-link repair in addition to its function as the 5' nuclease subunit of the excinuclease system.
Mismatch Repair
Mismatches in DNA result from replication errors, recombination, and deamination of cytosine or 5-methylcytosine (42) . The mismatched base is removed by a special repair system designed to recognize and eliminate mismatches from DNA (55) . Thus, this repair system differs from the other repair systems described so far in that the nucleotides that constitute the "lesion" are actually normal nucleotides; however, the DNA structure is abnormal because of base mispairing. The mismatches also can be removed either by base-excision or by nucleotide-excision mechanisms. The base-excision repair system is restricted in scope and hence will not be discussed. The general mismatch correction system appears to be the most important one, since it corrects all 12 possible mismatches as well as insertions and deletions. Hence, it is analogous to the nucleotide-excision repair system. It is referred to as the MutLS system (after proteins of the equivalent bacterial repair system) or the long-patch repair system because correction of the mismatch involves the removal of a long tract of DNA followed by synthesis of a long (up to 1000 nucleotides) repair patch (55) . Although the human mismatch repair system has not been reconstituted from purified proteins, genetic studies with mutant cell lines and biochemical experiments using cell-free extracts have led to the following model ( Fig. 1) : The mismatch is recognized by the hMSH2 (i.e., human MutS homologue 2)/GTBP (i.e, G-T binding protein; T = thymine) heterodimer (which is referred to as hMutSa); this complex is then recognized by the hMLHl (i.e., human MutL homologue l)/hPMS2 (i.e., human homologue of yeast post-meiotic segregation gene 2) heterodimer (which is referred to as hMutLcc), and an exonucleolytic degradation of DNA is initiated from a nick in the strand with the mismatch. Since a newly synthesized strand, by definition, contains the mismatch, it is presumed that the nicks of Okazaki fragments on the lagging strand and the 3' terminus of the leading strand, which are generated during DNA replication, provide the necessary signal for initiating the mismatch repair reaction.
Mismatch repair plays an important role in mutation/cancer avoidance. It has been found that a large fraction of hereditary nonpolyposis colon cancer (HNPCC) cases are caused by a mutation in MSH2/GTBP and MLH/PMS2 genes (55, 56) The current model is that, in HNPCC families, a recessive mutation is inherited from one parent and a mutation in the second allele in tissues that are not terminally differentiated generates a cell with no mismatch repair capability; hence, oncogenic mutation and malignant transformation occur. These tumors show extensive microsatellite instability because microsatellites (short repetitive sequences such as [GT] 30 ) are prone to mismatch formation during replication through polymerase slippage and realignment. In addition to HNPCC, microsatellite heterogeneity and mismatch repair defects have been detected in a number of sporadic tumors (57).
Postreplication Repair
As discussed above, the term postreplication repair is somewhat of a misnomer because it does not imply a unique repair process, but rather the ability of the cell to replicate past a lesion in the DNA. For that reason, the process is often referred to as replicative bypass. By allowing cells to escape S phase of the cell cycle without major gaps or discontinuities in their DNA, postreplication repair decreases cytotoxicity because: 1) cells maintain contiguous duplex DNA that can segregate normally during mitosis; 2) cells now have the entire G2 phase to repair interstrand cross-links and perhaps an entire cell cycle to repair the remaining monoadducts and intrastrand diadducts; and 3) replicative bypass avoids the accumulation of gaps in the DNA, which appear to activate signal transduction pathways controlled by p53 (55\59) or DNA-protein kinase (60, 61) . While these activated pathways can lead to protective responses such as cell cycle arrest (62, 63) , they can also lead to apoptosis and cell death (60, 61, (63) (64) (65) .
The enzymatic mechanisms of postreplication repair have not been characterized in detail. However, three general mechanisms for replicative bypass have been suggested (44) . First, translesion synthesis can be envisioned as replication directly past bulky adducts on the template. Presumably, this could occur by any process that decreases the fidelity or increases the processivity of DNA synthesis. Previous studies have shown that chain elongation by DNA polymerases a, 5, and e is effectively blocked by intrastrand Pt (66, 67) or UV radiation-induced (68) diadducts. Obviously, mutations in polymerase 8 or e that decrease the fidelity of replication could enhance translesion synthesis. In addition, the accessory protein PCNA has been shown to increase the processivity of DNA polymerase 8 (69) and has been shown to facilitate the bypass of UV radiation-induced (68) but not Pt-DNA (67) adducts. Thus, either the amount (70) (71) (72) , the distribution (75), or the association of PCNA with its inhibitory protein p21/WAFl (i.e., wild-type p53-activated fragment 1)/Cipl (i.e., cyclin-dependent kinaseinteracting protein 1) (74.75) could affect translesion synthesis. Similary, DNA polymerase (3 has been shown to be capable of displacing DNA polymerases a, 8 , and e from a replication complex that has been stalled at a Pt-DNA diadduct and elongating the daughter strand past the adduct (67) . Thus, differences in DNA polymerase P levels could affect translesion synthesis. The second mechanism suggested for replicative bypass involves the activation of alternate origins of replication near a site of damage, followed by gap filling. If the gap filling were performed by DNA polymerase P, it would be error prone. If the gap filling involved recombinational DNA-strand transfer, in analogy with one of the bacterial mechanisms of postreplication repair (76) , it would be largely error free. The third mechanism that has been suggested for replicative bypass involves template switching. In this mechanism, when replication of one strand of DNA is blocked by DNA damage, replication of the other strand would continue, followed by template switching so that the DNA polymerase could use the complementary daughter strand as a template instead of the damaged parental strand (77) . Presumably, this mechanism would be error free. While the enzymatic mechanism for template switching is not known, it is of interest that recent in vitro studies by Thomas et al. (78) have shown that, although a bulky adduct effectively blocks DNA synthesis on the damaged strand, replication of the undamaged strand continues for a short distance past the adduct. What this means in terms of the structure of the replication complex is not clear, but it could form the basis for template switching. For more complete discussions of postreplication repair, the reader is directed to reviews by Kaufmann (43) and Naegeli (44) .
Role of Repair in the Resistance to Chemotherapeutic Agents
In assessing the role of repair in resistance, there are several important points to consider. First, an increased rate of removal (or disappearance) of adducts suggests an increase in repair rate, but it does not indicate which pathway of repair is involved. Second, studies with cell lines that are deficient in one or more pathways of repair can demonstrate the participation of those pathways in the repair of a particular type of adduct, but they do not indicate whether the activity of those repair pathways is actually increased in resistant cell lines. Third, the demonstration that individual repair enzymes are present at higher levels in resistant cell lines does not prove unambiguously that a multienzyme repair pathway is enhanced, unless those enzymes can be shown to be limiting for that repair pathway and the repair pathway itself can be shown to be more active in the resistant cells.
Repair and Resistance to Pt Chemotherapeutic Agents
Overall repair. Many Pt-resistant cell lines appear to have enhanced repair activity based on the rate of disappearance of Pt adducts from unreplicated DNA (79) (80) (81) (82) (83) (84) (85) (86) , the rate of disappearance of interstrand cross-links (85) (86) (87) (88) , and the host-cell reactivation assay (89) (90) (91) . On the basis of those assays, repair activity is usually increased 1.5-fold to 2.0-fold in resistant cell lines. Nucleotide-excision repair is the only repair pathway known to repair Pt-DNA intrastrand diadducts (92, 93) . It is clear that the nucleotide-excision repair pathway is capable of repairing both Pt monoadducts and Pt intrastrand diadducts in vitro (94) (95) (96) (97) (98) 94, 99) . Among the intrastrand diadducts, GXG is repaired twofold to threefold faster than the GG and AG diadducts by both cell-free extracts and the purified human excision nuclease system (98, 100) . In analogy to what is found in Escherichia coli, the repair of Pt interstrand cross-links is likely to require some aspects of recombination in addition to nucleotide-excision repair (see above). It has been difficult to demonstrate enhanced nucleotide-excision repair activity directly in Pt-resistant cell lines, perhaps because of the inherent variability of the in vitro assay methods (707) (103), and the host-cell reactivation assay (104). Thus, while many Ptresistant cell lines display enhanced repair activity and it is very likely that this enhanced activity is caused by an increase in nucleotide-excision repair, it has been difficult to demonstrate increased nucleotide-excision repair activity directly in Pt-resistant cell lines. Recent refinements of the in vitro nucleotide-excision repair assay (49, 105, 106) should allow more precise determination of nucleotide-excision repair activity, but this assay has not been widely used for the comparison of activities in sensitive and resistant cell lines.
Fine structure of Pt adduct repair. Gene-specific repair has been demonstrated for Pt intrastrand and interstrand diadducts (85, 87, 107) , melphalan interstrand diadducts (20) , UV radiation-induced intrastrand diadducts (51, 108) , and psoralen interstrand diadducts (109). However, the contribution of gene-specific repair to resistance is unclear. For intrastrand diadducts, the relative repair rates in resistant and sensitive cell lines appear to be the same for actively transcribed genes and for genomic DNA (87) . In contrast, interstrand cross-links have been reported to be preferentially repaired in the actively transcribed dihydrofolate reductase (DHFR) gene but not in the total genomic DNA of two cisplatin-resistant cell lines (87) . However, this conclusion was based on the alkaline elution assay (7/0) for measurement of total Pt-DNA interstrand crosslink repair and an assay using renaturing agarose gel electrophoresis and Southern blotting (777) for measurement of interstrand cross-link repair in the DHFR gene. More recent studies have suggested that apparent differences in the repair rates of total genomic DNA and specific genes may be related more to differences in the assays used rather than to actual differences in repair.
1 In fact, when measured by the renaturing agarose gel-Southern blot assay, the rate of interstrand crosslink repair is esentially the same in actively transcribed genes, in inactive genes, and in noncoding regions of DNA (86, 87) . Thus, the current data do not appear to support a special role for genespecific repair in resistance.
There also appears to be an interesting sequence specificity to the repair of Pt-DNA adducts that is not entirely consistent with what is known currently about the specificity of the nucleotide-
-DNA adducts, and this technique has been used to quantitate the repair of each of those adducts in a variety of Pt-resistant cell lines. These studies appear to suggest the existence of two classes of Pt-resistant cell lines-those that repair Pt-AG adducts and Pt interstrand cross-links preferentially (772-775) and those that repair Pt-GG adducts preferentially (775) . (Repair of Pt-G and Pt-GXG adducts does not segregate consistently into either of the repair groupings.) The mechanism(s) for this unusual specificity is not currently known.
Damage recognition proteins and Pt resistance. In recent years, there has been considerable interest in the role that damage recognition proteins (DRPs; also known as structurespecific recognition proteins or SSRPs) might play in-Pt resistance. There is one group of proteins with "HMG (i.e., high mobility group)-domain" sequences that bind selectively to cisplatin-GG and -AG intrastrand diadducts but not to Pt monoadducts, cis-Pl GXG intrastrand diadducts, trans-Pi adducts, or UV radiation-induced adducts (116) (117) (118) (119) . The role of these Pt-DRPs in Pt resistance is not currently known. Since some of these HMG-domain proteins are known to be transcription factors, it has been suggested that their binding to Pt adducts may sequester them from their normal function and, thus, may affect the transcription of specific genes (720). It has also been suggested that HMG-domain proteins might interfere with the repair of Pt-DNA adducts. Studies have demonstrated that HMG-domain proteins can selectively inhibit the repair of Pt-DNA adducts by the human nucleotide-excision repair complex in vitro (98, 100) and that inactivation of a gene that encodes an HMG domain protein (IXR1) in yeast causes a twofold increase in resistance to cisplatin with no change in resistance to UV radiation (121) . However, the significance of these findings is unclear because no differences in steady-state levels of any HMG-domain protein have been seen in Pt-resistant cell lines and HMG-domain proteins do not appear to be damage inducible (116, 117) .
In contrast, UV radiation-damage recognition protein (UV-DRP; also known as damaged-DNA-binding protein [DDB]) or XPE-binding factor [XPE-BF]), a DRP with a high specificity for UV radiation-induced 6,4-photoproducts (122-124), has been reported to be present at higher levels in Pt-resistant cell lines that exhibit increased repair activity (measured by the rate of disappearance of Pt adducts and/or the host-cell reactivation assay) (125-127). However, recent in vitro reconstitution experiments have shown that XPE is not an essential part of the nucleotide-excision repair system (49) . Furthermore, Vaisman and Chaney (128) have characterized steady-state levels and induction by Pt of UV-DRP in a set of four sensitive and Pt-resistant cell lines. That study found no association between steady-state levels of UV-DRP and either Pt cytotoxicity or DNA-repair activity. The degree of Pt-inducible UV-DRP expression was greater in Pt-resistant cell lines, but there was no correlation between the Pt inducibility of UV-DRP and the repair activity of the resistant cell lines. Moreover, the kinetics of UV-DRP induction were much too slow (725) for the increase in UV-DRP activity to play an important role in the repair of Pt-DNA adducts (83, 84, 103) . Thus, the role of UV-DRP in both nucleotide-excision repair and Pt resistance is not clear at present. For more information on the role of repair in the resistance to Pt anticancer agents, the reader is referred to several additional reviews (129-133).
Repair and Resistance to CENUs
There has been considerable interest in the role of MGMT activity in the sensitivity to CENUs. As described above, the formation of N 3 C-N'G interstrand diadducts proceeds through the intermediate formation of O 6 G monoadducts and N',O 6 -ethano-G intramolecular adducts (27) . MGMT has been shown to remove O 6 -ethylG monoadducts (134). It also reacts with the N',O 6 -ethanoG adduct to form a complex in which the MGMT becomes irreversibly bound at N'G (27) . Both reactions prevent rearrangement to the very cytotoxic N^-N'G interstrand diadduct, although the cytotoxicity of the N'G-ethano-MGMT adduct is not known. Those 145, 148, 149) . Finally, a recent multicenter study (150) has suggested that variations in MGMT activity affect the therapeutic response of human brain tumors to BCNU in vivo.
Of course, MGMT is not likely to be the only enzyme involved in the repair of CENU adducts. MGMT is incapable of repairing the N 7 G monoadducts or the N 7 G-N 7 G diadducts. Furthermore, nucleotide-excision repair is known to repair O 6 -methylG adducts (105) and should be capable of repairing the N 3 C-N'G interstrand diadducts. Thus, it is not surprising that the available evidence suggests that the nucleotide-excision repair system is capable of repairing at least some of the cytotoxic lesions formed by CENUs (134,136,151) . However, those data do not demonstrate that increased activity of the nucleotide-excision repair pathway is involved in resistance to CENUs. The only evidence to date suggesting that increased nucleotide-excision repair activity contributes to CENU resistance is the cross-resistance to CENUs of some Pt-resistant cell lines (152-154) . However, this cross-resistance could be due to other resistance mechanisms in those cell lines, such as increased glutathione levels (155) or glutathione S-transferase activity (156). since some Pt-resistant cell lines characterized as showing increased removal of Pt-DNA adducts do not show cross-resistance to CENUs (112.153) .
Finally, E. coli 3-methyladenine-DNA glycosylase II has been shown to release 7-chloroethylG, 7-hydroxyethylG, and diguan-7-ethane from DNA treated with CENUs (157). Recent in vitro studies by Cappelli et al. (757) have also suggested that the base-excision repair pathway could contribute to the repair of both the N 7 G monoadducts and the N 7 G-N 7 G intrastrand diadducts but not of the highly cytotoxic N 3 C-N'G interstrand cross-links. However, whereas introduction of the human MPG gene into E. coli deficient in 3-methyladenine-DNA glycosylase II activity results in resistance to CENUs, overexpression of MPG in human cell lines does not alter sensitivity to CENUs (158). Thus, while variations in MGMT activity appear to play an important role in the cytotoxicity of CENUs, the contribution of the base-excision repair pathway to the repair of CENU adducts in vivo and the role of both the nucleotitie-and the baseexcision repair pathways in CENU resistance are not as clear. For more information on repair and resistance to CENUs, the reader is directed to several additional reviews (30, 31, (159) (160) (161) .
Repair and Resistance to Nitrogen Mustards
Increased disappearance of interstrand cross-links (162-164) and increased host-cell reactivation of plasmid DNA containing melphalan adducts (765) have been demonstrated for some nitrogen mustard-resistant cell lines and in chronic lymphocytic leukemia (CLL) cells from patients who have become resistant to nitrogen mustard therapy (166,167). Since interstrand crosslinks appear to be the major cytotoxic lesion for nitrogen mustards, it is logical that both the nucleotide-excision repair and recombination pathways would be critical for the repair of cytotoxic nitrogen mustard lesions. While cell lines lacking XP genes are not particularly sensitive to mechlorethamine, cells lacking ERCC1 (168) or overexpressing ERCC1 (769) are hypersensitive to mechlorethamine. In addition, several Pt-resistant cell lines characterized by an increased rate of Pt-adduct removal also show partial cross-resistance to melphalan and other nitrogen mustards (80, 152, 158, 170, 171) . Taken together, these data suggest a role for enhanced nucleotide-excision repair and/or recombination in resistance to nitrogen mustards. However, cross-resistance to cisplatin and nitrogen mustards could be caused by other resistance mechanisms, such as increased levels of glutathione (772), glutathione S-transferase (156,172,173 ), or metallothionein (774) .
In addition, E. coli 3-methyladenine-DNA glycosylase II has been shown to release N 7 G adducts from DNA treated with mechlorethamine (775) , suggesting that base-excision repair could play a role in the repair of nitrogen mustard adducts. Lymphocytes from CLL patients who have become resistant to nitrogen mustards and show enhanced removal of nitrogen mustard interstrand cross-links have increased levels of MPG (176,177). However, 3-methyladenine-DNA glycosylase II-deficient E. coli (alk A) are not particularly sensitive to mechlorethamine (178), and Chinese hamster ovary cells overexpressing MPG do not show increased resistance to melphalan (758). Thus, the role of base-excision repair in the repair of, and resistance to, nitrogen mustard adducts is not yet clear. For more information on the repair of adducts caused by nitrogen mustards, the reader is referred to the review by Povirk and Shuker (16) .
Repair and Resistance to Other Alkylating Agents
The role of repair in resistance is not as well characterized for busulfan and MMC as it is for the other chemotherapeutic agents discussed in this review. One busulfan-resistant cell line with increased repair of interstrand cross-links has been described (779) (181), decreased activation (182,183) , or increased levels of glutathione or glutathione S-transferase (184-186) as their primary mechanisms of resistance.
Postreplication Repair and Resistance
The suggestion that postreplication repair might play an important role in resistance is based primarily on studies of Ptresistant cell lines and is based on two lines of evidence: 1) a quantitative analysis of the ability of resistant cell lines to tolerate unrepaired adducts and 2) an analysis of the carrierligand specificity of Pt resistance. Several studies (187) (188) (189) (190) have identified enhanced tolerance of Pt-DNA adducts as a major mechanism of resistance in Pt-resistant cell lines that display little or no significant increase in repair activity.
In addition, many cell lines that are resistant to Pt compounds with the c/j-diammine carrier ligands, such as cisplatin and carboplatin, retain substantial sensitivity to Pt compounds with the diaminocyclohexane (dach) carrier ligand (80, 83, 84, 103, 191) . Conversely, dach-Pt-resistant cell lines often retain substantial sensitivity to Pt compounds with the cw-diammine carrier ligand (83, 192) . This dependence of resistance on the nature of the Pt carrier ligand has been referred to as the "carrier-ligand specificity of resistance" (83, 84) . In those Pt-resistant cell lines that have been studied in detail, the carrier-ligand specificity of resistance appears to be determined at the level of tolerance of Pt-DNA adducts (83, 84) . However, no carrier-ligand specificity has been observed for repair of total Pt-DNA adducts (83, 84) , total Pt-DNA interstrand cross-links, or Pt-DNA interstrand cross-links in an actively transcribed gene 1 . Thus, both lines of evidence suggested that, while enhanced removal of Pt-DNA adducts plays an important role in determining Pt resistance, differences in repair activity are probably not sufficient to explain fully the enhanced tolerance of Pt-DNA adducts. This led Gibbons et al. (193) to quantitate replicative bypass as a measure of postreplication repair in Pt-resistant cell lines. Those and subsequent studies by Mamenta et al. (190) have shown that replicative bypass is proportional to, and displays the same carrier-ligand specificity as, tolerance of Pt-DNA adducts in Pt-resistant cell lines. More recent studies have shown that cell lines with enhanced bypass of Pt-DNA adducts are cross-resistant to melphalan, cyclophosphamide, and BCNU and display enhanced bypass of melphalan-DNA adducts (Mamenta EL, Kaufman WK, Chaney SG: unpublished observations). These studies have suggested that postreplication repair makes a strong contribution to resistance against Pt compounds and bifunctional alkylating agents. Proof of this contribution will require a better characterization of the mechanism(s) of replicative bypass and the development of a sensitive in vitro assay for postreplication repair.
Defective Mismatch Repair and Resistance
Cell lines lacking MGMT are hypersensitive to methylating agents such as MNU (A'-methyl-N-nitrosourea) and MNNG (Nmethyl-yV'-nitro-iV-nitrosoguanidine), which cause the formation of O 6 -methylG adducts (194, 195) . It has long been known that a substantial proportion of naturally occurring revertants were generated by mutations at a second site rather than mutations restoring MGMT activity (196, 197) . Two studies (198, 199) have shown that some of the MGMT-deficient cell lines with enhanced tolerance of MNNG and MNU have defects in mismatch repair. These data have led to the hypothesis that an active mismatch-repair system might actually be detrimental for cells incapable of efficiently repairing O 6 -methylG adducts (198, 199) . Replication past an O 6 -methylG adduct frequently results in the formation of an O 6 -methylG-T mispair. The mismatch repair system would attempt to correct the mismatch by excising a tract of DNA from the newly synthesized T-bearing strand. Upon resynthesis, the O 6 -methylG-T mispair would form again with equal frequency, resulting in a futile cycling of mismatch repair and resynthesis that would prevent net DNA synthesis past the adduct. It is not known at this time whether defects in mismatch repair can also cause resistance to the chemotherapeutic alkylating agents. However, Duckett et al. (200) have shown that human MutSa recognizes cisplatind(GpG) adducts, and Anthoney et al. (201) have shown that a number of independently derived cisplatin-resistant cell lines have defects in mismatch repair. For additional information on mismatch repair and DNA damage tolerance, the reader is directed to reviews by Karran and Bignami (202) and Modrich and Lahue (55) .
DNA Damage-Inducible Repair and Resistance
The SOS response in E. coli is a damage-inducible response caused by bulky adducts that, among other things, leads to increased repair activity. In analogy to the SOS response of E. coli, there has been great interest in DNA damage-inducible responses that might lead to enhanced repair. However, there is very little evidence to date that DNA damage-inducible responses substantially affect repair in human cell lines. For example, MGMT activity is induced by DNA damage in rat hepatoma cells (203, 204) . The increase in MGMT activity is relatively small and is induced by heat shock and a wide variety of DNAdamaging agents not actually repaired by MGMT, such as UV radiation, cisplatin, and y radiation (203, 204) . Thus, the induction of MGMT has the characteristics of a generalized stress response rather than a response that plays an important role in the resistance to O 6 -G adduct formation. With respect to nucleotide-excision repair, several studies (205,206) have failed to detect the induction of genes directly involved in nucleotide-excision repair following exposure to DNA-damaging agents. However, Gadd45, one of several proteins induced by growth arrest and DNA damage, is induced by cisplatin and the bifunctional alkylating agents (207, 208) . This induction appears to involve transcriptional activation by p53 (208). Gadd45 binds to the replication and repair accessory protein PCNA with low. affinity (209, 210) . It has been reported that Gadd45 stimulates nucleotide-excision repair in vitro (209). However, a critical analysis of the effect of Gadd45 on the excision and repair synthesis steps of nucleotide-excision repair has shown that Gadd45 has no effect on either step of excision repair (211, 212) . In addition, the kinetics of Gadd45 induction are not compatible with an important role in repair, at least not in the repair of Pt-DNA adducts. Induction of Gadd45 by Pt compounds does not become substantial until 24 hours after treatment with a Pt drug, and it does not become maximal until around 40 hours after the beginning of treatment {213). On the other hand, the majority of Pt-DNA adducts are repaired within the first 6-8 hours following Pt treatment {83, 84, 103) .
More direct effects of p53 on nucleotide-excision repair have also been postulated {214,215), in part because p53 has been shown to bind XPB (ERCC2) and XPD (ERCC3) (276). However, cell lines with defective p53 function have been reported to be both sensitive {214,215) and resistant {201) to DNAdamaging agents such as UV radiation or cisplatin. Similarly, while disruption of p53 function by the E6 oncoprotein of human papillomavirus type 16 and the product of a dominantnegative mutant p53 transgene have been reported to decrease the repair of UV radiation-induced {214) and cisplatin (275) adducts, p53 (-/-) cells excise pyrimidine dimers and 6,4-photoproducts at the same rate as wild-type cells (277). Finally, p53 protein has no effect on excision repair in a defined system (Kazantsev A, Sancar A: unpublished observations). Thus, current data do not appear to support a direct role for p53 in nucleotide-excision repair.
Expression of Repair Genes in Resistant Cell Lines
There has been considerable interest in the expression of individual repair genes, both as possible markers for enhanced repair activity in resistant cell lines and as possible prognostic indicators of the likely therapeutic response of tumors to DNAdamaging chemotherapeutic agents. The association between DNA repair and gene expression is clearest for MGMT, where there is a clear correlation between MGMT expression and resistance to CENUs in cell culture {137, 145, 148, 149) . As discussed above, MPG levels are increased in some cell lines that are resistant to nitrogen mustards and CENUs {176, 218, 219) , but overexpression of MPG does not appear to increase the resistance to either agent directly {158).
Several laboratories have reported that DNA polymerases a and (3 are overexpressed in Pt-resistant {220,221) and melphalan-resistant (765) cell lines. Ali-Osman et al. {222) have also reported enhanced repair activity and increased expression of DNA polymerase a, DNA polymerase P, and DNA ligase in cells from human tumors following cisplatin treatment in vivo. However, the significance of these observations is not clear. As noted above, DNA polymerase P does not appear to be involved in nucleotide-excision repair, although it may be involved in postreplication repair. In addition, other studies (714,205,206) have reported no change in either DNA polymerase a activity or DNA polymerase p activity in cell lines resistant to both cisplatin and alkylating agents.
Expression of the XPA and ERCC1 genes has been reported to be greater in the tumor tissue of some patients with malignant ovarian cancer who did not respond to Pt-based chemotherapy than in the tissue of responders {223,224). However, the basis of these differences is also not clear. Neither XPA nor ERCC1 is known to be rate limiting for nucleotide-excision repair. While transfection of an XPA-expression vector into XPA-deficient cell lines can restore nucleotide-excision repair activity, overexpression of the same plasmid in repair-proficient cell lines does not appear to have any substantial effect on activity levels {225).
ERCC1 levels are not increased in some Pt-resistant {205,206) and melphalan-resistant (762) cell lines characterized by increased repair activity. In addition, while transfection of ERCC1 restores repair of interstrand cross-links in cell lines that are deficient in this protein {169,226), overexpression of ERCC1 actually appears to inhibit repair of interstrand cross-links (769). Finally, while an initial study of CLL patients (777) suggested that overexpression of ERCC 1 was associated with a failure to respond to nitrogen mustard treatment, a subsequent study (7 76) found no difference in expression of ERCC1, XPD (ERCC2), DNA polymerase p, or topoisomerase I between responding and nonresponding patients. Similarly, a breast carcinoma cell line characterized by enhanced repair activity and resistance to both cisplatin and bifunctional alkylating agents did not display increased expression of ERCC1, XPD (ERCC2), XPB (ERCC3), DNA polymerase p, AP endonuclease, or MPG (765). Thus, there is no clear evidence of overexpression of nucleotide-excision repair genes in resistant cell lines or in resistant tumors at present, but studies comparing the expression of these genes with therapeutic response are continuing and may provide additional insights into this question.
Into the Next Century: Clinical Strategies for Modulating Repair Activity
While uncertainties remain, it appears likely that DNA repair contributes to resistance to bifunctional chemotherapeutic agents. Certainly, many Pt-resistant cell lines have increased repair activity, and it is likely that this primarily represents an increase in nucleotide-excision repair. Whether the repair of Pt interstrand cross-links makes an independent contribution to Pt resistance is not currently known. Similarly, resistance to CENUs appears to be determined in part by MGMT levels, with possible contributions by both nucleotide-and base-excision repair. Finally, some nitrogen mustard-resistant cell lines show increased repair of interstrand cross-links, suggesting an increase in the nucleotide-excision/recombination-repair pathway. Definitive proof that individual repair pathways contribute to resistance will require the development and utilization of quantitative and reproducible in vitro repair assays (706) and more selective repair inhibitors {see below).
To the extent that enhanced repair activity does contribute to resistance, it should be possible to improve the efficacy of bifunctional chemotherapeutic agents by interfering with repair of the adducts that they form. However, there are several major barriers to the application of such a strategy. Foremost among these barriers is the multifactorial nature of resistance. Decreased accumulation {79, 83, 84, [227] [228] [229] [230] , increased efflux {231,232), increased inactivation by glutathione {155,172, [233] [234] [235] [236] [237] , by glutathione S-transferase {156,173. 238, 239) , or by metallothionein {174, 240, 241) , altered metabolism {242), and increased tolerance of unrepaired damage {83, 84, 86, 112, 187, 188) contribute to resistance to all of the chemotherapeutic agents discussed in this review. Repair activity is usually enhanced only 1.5-fold to 2.0-fold, even in cell lines that are 20-fold to 100-fold resistant to chemotherapeutic drugs {85, 103) . However, even a 1.5-fold to 2.0-fold decrease in repair activity might be enough to bring the response of some resistant tumors into the therapeutic range, especially if inhibitors of repair activity could be combined with agents that block other mechanisms of resistance.
Unfortunately, many of the strategies employed to date have not been truly selective for inhibition of DNA repair, and/or they have resulted in only marginal improvements in therapeutic index. For example, DNA polymerase inhibitors, such as aphidicolin (a selective inhibitor of DNA polymerases a and 8) and cytarabine (i.e., cytosine arabinoside) have been tested in combination with several of the chemotherapeutic agents discussed in this review as inhibitors of the resynthesis step of nucleotide-excision repair. While some of these combinations may prove to be clinically useful, such inhibitors cannot be considered true repair inhibitors. They are likely to affect DNA synthesis as well as DNA repair, and they may affect normal cells as well as tumor cells. Similarly, there has been considerable interest in modulating the sensitivity to bifunctional chemotherapeutic agents through activation or inactivation of various signal transduction cascades (243, 244) . Of the interactions studied to date, activation of the protein kinase C (245), EGF (246, 247) , and HER-2/neu (248,249) signal transduction pathways has been reported to decrease the repair of Pt-DNA adducts. However, the effects of these signal transduction pathways on DNA repair are relatively modest and are insufficient, by themselves, to explain the enhancement of cisplatin cytotoxicity (244) . Thus, while modulation of some signal transduction pathways may prove clinically useful for increasing tumor sensitivity to bifunctional chemotherapuetic agents, it appears that alteration of repair activity makes only a minor contribution to these interactions.
There has also been considerable interest in the inactivation of MGMT as a means of potentiating CENU chemotherapy. For example, monofunctional alkylating agents such as MNNG, MNU, dacarbazine, or streptozotocin strongly potentiate the cytotoxicity of CENUs in MGMT-containing cell lines (141,142). However, monofunctional alkylating agents have substantial cytotoxicity themselves and are potent mutagens and carcinogens (159, 195) . The combination of steptozotocin plus BCNU was evaluated in two phase I clinical trials. In both trials, the toxicity of BCNU was greatly increased without any evidence of improved therapeutic response (250, 251) . Similarly, a combination of dacarbazine and the CENU fotemustine had to be discontinued because of unexpected lung toxicity (252) . More recently, it has been shown that exposing cells to O 6 -methylguanine or O 6 -benzylguanine results in inactivation of MGMT and potentiation of CENUs (135, 143, 144) . This strategy is currently being evaluated in clinical trials.
In looking toward the future, it should be possible to capitalize on recent advances in our understanding of the adducts formed by chemotherapeutic agents and the mechanisms for repair of those adducts to design more effective strategies for overcoming the repair component of drug resistance, whether intrinsic or acquired. It is clear that there is a need for more selective inhibitors of repair than those used in the past. O 6 -Benzylguanine is a possible example of the kind of highly selective repair inhibitor that may be needed. No such selective inhibitors of base-excision repair or nucleotide-excision repair are currently known; however, with the recent complete characterization of the nucleotide-excision repair system (49) and the development of sensitive in vitro assays (49, 105, 253) , it should be possible to design and test such inhibitors. Since repair also protects normal tissues, the selective delivery of such repair inhibitors to tumor tissue must be considered. Finally, replicative bypass (postreplication repair) appears to make a substantial contribution to the tolerance of unrepaired DNA adducts (190, 193) . Once the enzymatic mechanism(s) of replicative bypass are known in more detail, it should be possible to design inhibitors of replicative bypass that, along with more selective repair inhibitors, could greatly increase the efficacy of Pt drugs and bifunctional alkylating agents against currently resistant tumors.
